Alzamend Neuro announced on May 29, 2025, the dosing of the first patient in its first Phase II clinical study of AL001. This study involves healthy human subjects and is taking place at Massachusetts General Hospital.
The trial aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. This is a significant step in evaluating AL001's enhanced safety and brain targeting capabilities.
The company expects to announce topline data from this study before the end of 2025. The dosing of the first patient marks further tangible progress in the clinical development of AL001, which is being developed for multiple neuropsychiatric and neurodegenerative conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.